{"name":"Alentis Therapeutics AG","slug":"alentis-therapeutics-ag","ticker":"","exchange":"","domain":"alentis.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ALE.P02","genericName":"ALE.P02","slug":"ale-p02","indication":"Other","status":"phase_1"},{"name":"ALE.P03","genericName":"ALE.P03","slug":"ale-p03","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ALE.F02","genericName":"ALE.F02","slug":"ale-f02","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"ALE.F02","genericName":"ALE.F02","slug":"ale-f02","phase":"phase_2","mechanism":"ALE.F02 is a small molecule targeting the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"ALE.P02","genericName":"ALE.P02","slug":"ale-p02","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALE.P03","genericName":"ALE.P03","slug":"ale-p03","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOZlBaaUpXNWNVVnVqMVhMaTV0azAyZl9MeVgya21BemUtWkItcGZlcVZZNzNuS0FfMEQ4WXc4S3llbnZSamtSNXU0cDVZejd2ZVlQYzUydTV3RE9tUDBJaUdzUzFDYkVkcmpaYk8tdEM4TnJfTXNxMHBYNEJ0VmtYbTV3TWJ2bFdTQzdMY29MLUFILVltZ1pjQl9SYw?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Growth Patterns, Segment Analysis, and Competitive Approaches - openPR.com","headline":"Growth Patterns, Segment Analysis, and Competitive Approaches","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQd2wtajMzczNvQXQ2NHVPb1k5VVFJTHB6RnBwd01QWnZTbWtHT1V3R1EwSElhZVAtZkRnV1JwRzlUS1llZjlMTGVBbTN6cGJrWFI4SXVUSHd1WWdzekk0VzFHQ1o3ME53RThZQmZSNXdDZnZLZnhUSmlUcUx1aXk0UjhfbWVVTlZOWThWMlpXajRBc05hMnBEZnMweE55ekRxWEpXVnM3ZkJ5bmhzTGdYa0RGSkR4TmFzbjdfd2ZTYzhwa0NubHFLcGZKZ1NnVDc0RElkUDl2U3VGdEY1NnFPdG1kMC1YbGxFckc1R2dEOVFvdVpfbDk0?oc=5","date":"2025-10-22","type":"regulatory","source":"prnewswire.com","summary":"Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight - prnewswire.com","headline":"Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPcjBOOEdPSlFTcThvZGhFaW1pa3FrdU5Dc2VrcUU4QjNBRXU1bUZZWnRmZV9hSEhhbjlWUE9mWWc1R0t2NEQ0OFJScG9TeGVKREhON25QTDNrdEZFd3lxQ3VreGxJOUVpWHozN0p4UjdjVDVhbEk1RXAtMUZiZ1l5dkFqV09wT21yUk1jYTZ6dXNEck9UcGZyRTZfaVRUUlhuUjJqWGt3Zlo4V1R5bm5GTg?oc=5","date":"2025-10-17","type":"pipeline","source":"OncLive","summary":"First-Line Alectinib Yields Clinically Meaningful OS Benefit in Advanced ALK+ NSCLC - OncLive","headline":"First-Line Alectinib Yields Clinically Meaningful OS Benefit in Advanced ALK+ NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNZDJ2dUU3LUtocmI0S200ZDBxREczWlRQSktVcFA5a3hTdkZkbVRaTlBicC1rUUZNSnV0c2I2TFhURVY0MlJEZ3ktakVlQUZ2R1ItZktzSWtrVlBDR0lMZ295bzQzdjFGUTYtZWJmd2EyYllJakxscXpXUlg1Q2M2ZW1vQzZFa1BNSFhpV3NuMHNtcHc?oc=5","date":"2025-10-17","type":"pipeline","source":"Targeted Oncology","summary":"Durvalumab Plus FLOT Improves OS in G/GEJ Adenocarcinoma - Targeted Oncology","headline":"Durvalumab Plus FLOT Improves OS in G/GEJ Adenocarcinoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQbVJQQXhxOVQ4VmFMckt2cXJwLThXMlBfVE92Y0MzUWhrS196bDh3Ullua1NQei1VaFpWSTRXdURSZDdQYXRDUEhGam1PM2lPRzBQR1NsTUxoNG5vcE5uaHo3OU1MY0c1czk3MUt5R3pqX2NsSjBzbU45d3M3aEdqSXZwS0ZyNkdhNU5HNU54Szk2TnpxR19Z?oc=5","date":"2025-10-17","type":"pipeline","source":"startupticker.ch","summary":"New leadership drives growth in biotech and AI startups - startupticker.ch","headline":"New leadership drives growth in biotech and AI startups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9vRmJsZ1NIQ2dWRGJZQ0JNakc2ckxpYjVod2x3RXNIN1Q3Y3c0Q0VrSVdGR0tQd2VXbzlScm9yeXd6Vl9DR1duZjNZTkRvWTNtSXlldmVrbmY3SHhuMEFLNjAzNWRGckhWaUwtZWpUWlM2cVFlUUpiWkNqTDg?oc=5","date":"2025-10-15","type":"pipeline","source":"BioCentury","summary":"Pruzanski named CEO of Alentis - BioCentury","headline":"Pruzanski named CEO of Alentis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxOOGhwejFnY0Z0ZzVzLVFQT3BaMWZCbTRGT3JXNTJ6MWVlT3RfaXNfbDRJZEhETlk0VGFoM1FZRHQyZ3dzVFJyWV9nQ0N6bXZucjRweFRHTFF2bTQyX09CVjBEeGZpV0dNeHRrck8wZ01TTmIzSGN6T0ZNWXVDVTZxRER4cUZDdDAyRC01RzVoM3NySFpHN0F6V2dRcHZxTnI5YVdIYUp1YWdDclFPZTFMei1EWndLRERFMEUyZDRZMDhXNkNfRGJ0dFF4TVdGUU5oZE9VV3VuaDBYN0F6YUh2aUZZLU53MXFsbkpIZ19hZ3RGZThOd1JNRTZEWmlnckN0M0ZKZm9UNXZKNjhqWW9nYjA1T3ljZG5LVXZOLTB4eHZ6NEU4MHc1Ul9XV1lxNnZaZUtUdkxnSGJONGpP?oc=5","date":"2024-11-12","type":"pipeline","source":"businesswire.com","summary":"Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors - businesswire.com","headline":"Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development o","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNdFlzZDJGbnRBWEh6bFhpbEc3M3lBenZUbWE3QVY2MFBWVEdYektZOFlMQzZfTHNvOXlrQlA4aUdBRHEzQ29Ea0ZTeE00RkFZQ3QtSG9vSUlCWkpZQ3d2Y21UdlowYzNTODRsTDdBdXNicS04MXNzVEhHRlU3eFFaUFJ6cVlaX01IZzd0WjN1bXVfOUNPLVJJUmpB?oc=5","date":"2024-04-23","type":"pipeline","source":"European Biotechnology Magazine","summary":"Swiss Biotech Report reporting record turnover - European Biotechnology Magazine","headline":"Swiss Biotech Report reporting record turnover","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNMUlkbUo2d0Q0SHNwTXIzbmxqd1FDU2JHSWdVclN6ZUVOUVVsRjhJY0lvekItMGc3dV92cXV6dXFOX3NlX0pJcy0yV08ycVNVc19qcXUxOElyZVRJSEVGODBXV1JLMXE0SGhqcHlnRTRtOGcwN2V4UWstQXR6bWd3ZFB5Ml9BTXFwYlpGT0pVdG1fMktrNUhKTk96ei1FMHgzaXpGeGk0Ym8?oc=5","date":"2023-01-06","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—2 more C-suite members leave Galapagos island - Fierce Biotech","headline":"Chutes & Ladders—2 more C-suite members leave Galapagos island","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNNVdNanhvTFdlaGZCZk9zNUNja08wTmdtd3l3TV9TSmNLQngxRVp2WWNQVlM2WnJrS255dTcyNjFuSXFZcVRrQ0JZQlRCYnFYQXczY2o5aDlZQ0JXOHEzaG9vYV9RaXFXdEtCLTFMYjhCeVR1T0Nxcno3YjJjMWhXYw?oc=5","date":"2021-05-10","type":"pipeline","source":"channeleye.media","summary":"Pureos Bioventures supported on debut fund launch by Carey Olsen and Northern Trust - channeleye.media","headline":"Pureos Bioventures supported on debut fund launch by Carey Olsen and Northern Trust","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}